Invention Grant
![Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR](/docs/US/2019-08-13/US10376531B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
-
Application No.: US16023232Application Date: 2018-06-29
-
Publication No.: US10376531B2Publication Date: 2019-08-13
- Inventor: Spiros Liras , Vincent Mascitti , Benjamin Thuma
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent Lisa A. Samuels
- Main IPC: C07D493/08
- IPC: C07D493/08 ; A61K31/357 ; A61K31/706 ; C07D309/14 ; C07H13/04 ; C07H15/26 ; A61K31/7008 ; A61K31/7056 ; A61K38/46 ; C07H15/08 ; C07H15/12 ; C07K5/065 ; A61K47/64
![Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR](/abs-image/US/2019/08/13/US10376531B2/abs.jpg.150x150.jpg)
Abstract:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
Public/Granted literature
- US20180296585A1 SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR Public/Granted day:2018-10-18
Information query
